Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Larimar Therapeutics, Inc. (LRMR)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
3.1600-0.0100 (-0.32%)
At close: 04:00PM EST
3.1600 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1700
Open3.1200
Bid3.0400 x 800
Ask3.2600 x 1800
Day's Range2.9600 - 3.2000
52 Week Range1.5300 - 11.3100
Volume56,211
Avg. Volume173,911
Market Cap55.965M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

    BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company’s presentation will take place on Thursday, December 1, 2

  • GlobeNewswire

    Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

    First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timelineLarimar expects to provide an update on the Phase 2 trial in Q2 2023 and anticipates reporting top-line data from both cohorts in 2H 2023Cash of $124.7 million at September 30, 2022 provides projected cash runway into 2H 2024 BALA CYNWYD, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR

  • GlobeNewswire

    Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

    BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim 4th Annual Immunology & Neurology Day, which is taking place from November 14 – 15, 2022. Details on the fireside chat can be found below. Date:Tuesday, November 15,

Advertisement
Advertisement